Sheet <u>1</u> of 6

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE ATTY. DOCKET NO .: SERIAL NO.: PATENT AND TRADEMARK OFFICE PD01059KQ TO BE ASSIGNED APPLICANT: INFORMATION DISCLOSURE STATEMENT WING-KEE PHILIP CHO BY APPLICANT GROUP: FILING DATE: (Use several sheets if necessary) 11/03/2002 1615 U.S. PATENT DOCUMENTS EXAMINER DOCUMENT DATE NAME CLASS SUB-FILING DATE IF INITIAL CLASS APPROPRIATE NUMBER 7HS/ 02/18/2003 AA 6,521,254 B2 Weinstein, et al 424 468 AB 6,514,520 B2 02/04/2003 Munayyer, et al 424 439 AC 6,506,767 B1 01/14/2003 Schumacher, et al 514 290 AD 6,132,758 10/17/2000 Munayyer, et al 424 439 ΑE 6,100,274 08/08/2000 514 290 Kou AF 6,051,585 04/18/2000 Weinstein, et al 514 335 5,939,426 08/17/1999 AG McCullough 514 290 Handley, et al. AH 5,900,421 05/04/1999 514 290 5,731,319 03/24/1998 Aberg, et al. 290 Αl 514 ΑJ 5,595,997 01/21/1997 Aberg, et al. 514 290 AK | 5,476,856 12/19/1995 Carceller, et al 514 290 AL 5,407,941 04/18/1995 Carceller, et al 514 290 AM 5,314,697 05/24/1994 Kwan, et al. 424 480 AN 5,100,675 03/31/1992 Cho, et al. 424 468 AO 5,089,496 Piwinski, et al. 02/18/1992 514 253 AP 5,019,591 05/28/1991 Gardner, et al. 514 461 02/05/1991 AQ 4,990,535 514 Cho, et al. 556 AR 4,906,647 03/06/1990 Kouchiwa, et al 514 356 AS 4,863,931 09/05/1989 Schumacher, et al. 514 290 6.270.796 B1 08/07/2001 ΑT Weinstein, et al 424 457 7HS/ ΑU 4,804,666 02/14/1989 Piwinski, et al.. 514 278 FOREIGN PATENT DOCUMENTS DOCUMENT DATE COUNTRY CLASS SUB-TRANSLATION NUMBER CLASS YES NO 7HS/ 0 264 259 A1 04/20/1988 ΑV **European Patent Office** A 61 K 31/44 AW 0 288,640 A1 11/02/1988 **European Patent Office** A61K 31/445 0 396,404 A1 11/07/1990 **European Patent Office** 31/445 AX A61K AY 0 396,404 B1 02/16/1994 **European Patent Office** A61K 31/445 **European Patent Office** AZ | 0 577 957 A1 01/12/1994 C07D 401/00 BA WO 85/03707 08/29/1985 **WIPO** /HS/ BB WO 92/00293 01/09/1992 WIPO OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) Andersen, et al., "Adverse drug interactions clinically important for the dermatologist", Arch /HS/ Dermatol, April, 1995, Vol.131, pp. 468-473. BD Babe, et al., "Histamine, Bradykinn, and their Antagonists" in The Pharmacological Basis of /HS/ Therapeutics (9th edition), The McGraw-Hill Co. Inc., pp. 581-599 (1996). Barnett, et al., "Pharmacology of Non-Sedating H1 Antihistamines", New Perspectives in /HS/ Histamine Research, Birkhauser Verlag Basel, pp. 181-196 (1991). **EXAMINER** DATE CONSIDERED /Humera Sheikh/ 07/26/2007 \*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 2 of 6

FORM PTO-1449  U.S. DEPARTMENT OF COMM				•			SERIAL NO.:		
PATENT AND TRADEMARK O				PD01059KQ TO BE ASSIGNED					
INFORMATION DISCLOSURE STATEMEN BY APPLICANT			ATEMENT	APPLICANT: Wing-Kee Pl					
	<i></i>			•	FILING DATE: GROUP:				
(Use several sheets if necessary)				ary) 	11/03/2003	1615			
			U.S. P	ATENT DOCU	MENTS				
XAMINER INITIAL		DOCUMENT NUMBER	DATE	NAN	IE	CLASS	SUB- CLASS	FILING APPRO	
/HS/	BF	4,783,465	11/08/1988	Sunshine, et al.		514	255	AFFRO	FINA
/11O/ *	BG		10/11/1988	Heinrich		514	226.2	<del> </del>	
	ВН		03/15/1988	Schumacher, et	 al	546	93	<b>†</b>	
-	BI	4,659,716	04/21/1987	Villani, et al.	ui.	514	290	<del>                                     </del>	
-	BJ	4,552,899	11/12/1985	Sunshine, et al.	<del> </del>	514	568	1	
<del></del>	BK	4,371,516	02/01/1983	Gregory, et al.		424	22	1	
-	BL	4,282,233	08/04/1981	Vilani		424	267	<b> </b>	
<del></del>	ВМ	4,008,796	02/22/1977	Aylon		198	460		
1/	BN	3,940,485	02/24/1976	Levinson, et al.		424	250		
₩	ВО	3,916,899	11/04/1975	Theeuwes, et al.		128	260	<del> </del>	
<del>/HS/</del>	BP	3,845,770	11/05/1974	Theeuwes, et al.		128	260		
		0,0.0,7.70		PATENT DOC	NIMENTS	1 .20	1200		
		DOCUMENT	DATE	COUNTRY	OMENIS	CLASS	SUB-	TRANS	LATIC
		NUMBER		COOKINI		02.00	CLASS	YES	NO
7HS/	BQ	WO 92/11034	07/09/1992	WIPO					1
/HS/	BR	WO 92/20377	11/26/1992	WIPO					1
/HS/	BS	WO 96/20708	07/11/1996	WIPO					<u> </u>
/HS/	ВТ	WO 96/16641	06/06/1996	WIPO					ĺ
/HS/	BU	WO 98/34614	08/13/1998	WIPO					
	ОТ	HER DOCUME	NTS (Includ	ling Author, Titl	e. Date. Pert	inent Pa	ages. Et	c.)	
/HS/	BV	Berge, et al., "Ph		Salts", J. of Pharm					pp.1-
		19.							
/HS/	BW	Berthon, et al., "In Vitro inhibition, by loratadine and descarboxyethoxyloratadine, of histamine release from human basophils, and of histamine release and intracellular calcium fluxes in rat							
/113/									
	DV.	basophilic leukemia cells (RBL-2H3)", Biochem. Pharm., 1994, Vol. 47, No.5, pp. 789-794.  Blaug, et al., "Interaction of dextroamphetamine sulfate with spray-dried lactose", J. of Pharm.							
/HS/	BX					ay-ariea ia	ictose", J	. or Pna	rm.
	BY	Sciences, November, 1972, Vol. 61, No.11, pp. 1770-1775.  Brandes, et al., "Enhanced cancer growth in mice administered daily human-equivalent doses of							
/HS/	- '	some H1-antihistamines: predictive in vitro correlates", J. of the National Cancer Inst., May 18,							
,,,,,,,,		1994, Vol. 86, N						. ,	,
/HS/	BZ	Brandes, et al., "	Stimulation of	malignant growth			ant drug	s at clini	ically
		relevant doses",	Cancer Resea	rch, July 1,1992, \		6-3800.			
XAMINE	Κ .	n: 0: :	,	DATEC	ONSIDERED	V.	7/96/900	7	
		/Humera Shei	kn/		07/26/2007				
			onsidered, whe					_	

33723

applicant.

1069km223\_0fA116 **FORM PTO-1449** U.S. DEPARTMENT OF COMMERCE SERIAL NO.: ATTY, DOCKET NO.: PATENT AND TRADEMARK OFFICE PD01059KQ TO BE ASSIGNED APPLICANT: INFORMATION DISCLOSURE STATEMENT Wing-Kee Philip Cho BY APPLICANT FILING DATE GROUP: (Use several sheets if necessary) 11/03/2003 1615 U.S. PATENT DOCUMENTS EXAMINER DOCUMENT DATE NAME CLASS SUB-FILING DATE IF INITIAL /HS/ NUMBER CLASS APPROPRIATE CA 3,598,123 08/10/1971 128 Zaffaroni 268 CB 3,536,809 10/27/1970 424 28 /HS/ **Applezweig** FOREIGN PATENT DOCUMENTS DOCUMENT DATE COUNTRY **CLASS** SUB-TRANSLATION **NUMBER** CLASS YES NO /HS/ 01/20/2000 PCT International WO 00/2560 OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) Brion, et al., "Evaluation of the antimuscarinic activity of atropine, terfenadine and meguitazine in /HS/ healthy volunteers", Br. J. Clin. Pharmac. 1988, Vol. 25, pp.27-32 Carmeliet, "Voltage- and Time-Dependent Block of the Delayed K+ Current in Cardiac Myocytes by Dofetilide", The J. of Pharm. And Experimental Therapeutics, 1992, Vol. 262, No. 2, pp. 809-817. CF Castello, et al., "Discoloration of tablets containing amines and lactose", J. of Pharm. Sciences, February, 1962, Vol. 51, No.2, pp. 106-108. Cheung, et al., "Investigation of anti-motion sickness drugs in the squirrel monkey", J. Clin. Pharmacol, 1992, Vol. No. 32, pp. 163-175. Clissold, et al., "Loratadine: A preliminary review of its pharmacodynamic properties and therapeutic efficacy", Drugs, 1989, Vol. 37, pp. 42-57. CI Cooke, "Glycopyrrolate in bladder dysfunction", SA Medical Journal, January 1,1983, p. 3. Craft, "Torsade de pointes after astemizole overdose", Br. Medical Journal, 1986,, Vol. 292, p. 660. Dorje, et al., "Antagonist Binding Profiles of Five Cloned Human Muscarinic Receptor Subtypes", CK The J. of Pharm. And Experimental Therapeutics, 1991, Vol. 256, pp. 727-733. Drug Facts and Comparisons, 1998 Ed., Facts and Comparisons, St. Louis, Missouri, p. 2832. CL СМ Ebert, "Soft elastic gelatin capsules: a unique dosage form", Pharmaceutical Technology, 1977, pp. 44-50. Gengo, "Dilemma: Antihistamine selection: Use vs. Side effects", U.S. Pharmacist, November, 1990, pp. 59-92. CO Hartauer, et al., A Comparison of Diffuse Reflectance FT-IR Spectroscopy and DSC in the Characterization of a Drug-Excipient Interaction, "Drug Development and industrial Pharmacy", 1991, Vol. 17, No. 4, pp. 617-630. Herron, et al, "Dose Proportionality, Linearity, and Pharmacokiinetics of Desloratadine in Healthy Volunteers" (Abstract 1126), J. Allergy Clin. Immunol., January, 2000, Vol. 105, No. 1, Part 2, p. S385. Herzog, et al., "Urinary Incontinence: medical and Psychosocial Aspects", Annual Review of Gerontology and Geriatrics, 1989, Vol. 9, pp. 74-119. CR Hilbert, et al., "Pharmacokinetics and Dose Proportionality of Loratadine", J. Clin. Pharmacol. 1987, Vol. 27, pp. 694-98. Housley, et al., "Histamine and related substances influence neurotransmission in the CS semicircular canal", Hearing Research, May 1, 1988, Vol. 35, pp. 87-97. Jankowski, et al., "Effect of Terfenadine on Nnasal Provocation", Int. Arch. Allergy Immunolog., 1993, Vol. 101, pp. 311-317. Kaliner, "Nonsedating Antihistamines: Pharmacology, Clinical Efficacy and Adverse Effects", American Family Physician, March, 1992, Vol. 45, No. 3, pp. 1337-1342. Kleine-Tebbe, et al., "Inhibition of IgE- and non-IgE-mediated histamine release from human basophil leukocytes in vitro by a histamine H1-antagonist, desethoxycarbonyl-loratadine", J. Allergy Clin. Immunol., 1994, Vol. 93, pp. 494-500. Knowles, "Astemizole and Terfenadine-Induced Cardiovascular Effects", The Canadian J. of /HS/ Hospital Pharmacy, February, 1992, Vol. 45, No. 1, pp. 33 & 37.

/Humera Sheikh/

**EXAMINER** 

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line

DATE CONSIDERED

07/26/2007

through citation if not in conformence and not considered Rich to x0200 this vormer it is not considered Rich to x0200 this vormer is not

Sheet 4 of 6

						,			<u>4</u> of	6	
FORM PTO-1449  U.S. DEPARTMENT OF COMIPATION AND TRADEMARK OF INFORMATION DISCLOSURE STATEME BY APPLICANT  (Use several sheets if necessary)					ATTY. DOCKE PD01059KQ	SERIAL NO.: TO BE ASSIGNED					
					APPLICANT:		TO BE ASSIGNED				
					Wing-Kee Philip Cho						
			arv)		FILING DATE:	<u></u> .	GROUP	;			
				<del></del>	11/03/2003			1615			
+=>^^		DOO! IMENIT		ATENT DOC			T 01 400	1	leu wa		
*EXAMINER INITIAL	1	DOCUMENT NUMBER	DATE	N	ΑN	1E	CLASS		FILING I APPRO		
	-						ļ		<del> </del>		
	1			<u> </u>							
	<u> </u>					<del></del>					
		F	OREIGN	PATENT DO	OC	UMENTS					
	1	DOCUMENT DATE		COUNTRY			CLASS	SUB-	TRANS	LATION	
		NUMBER						CLASS	YES	NO	
	-		<u>.                                    </u>						<del> </del>	<del> </del> -	
	OT	HER DOCUMENT	S (Includ	ling Author 7	-i+l	e Date Per	tinent Pa	anes Et	<u> </u>		
/HS/		Kohl, et al., "Lack of l								nitive	
77107	ļ	Performance in Man", Aviation, Space, and Environmental Medicine, December, 1987,							987, pp. 1171-1174.		
	CY	Kohl, et al., "New Pha   Pharmacol., 1991, Vol			e P	revention of Spa	ice/Motion	Sickness'	', J. Clin.		
	CZ				autonomic dysfunction with terfenadine, a peripherally acting						
			antihistamine", Aviation, Space and Environmental Medicine, May, 1991, pp. 392-396.								
	DA Kreutner, et al, "Profile of Desloratadine as a Selective and Non-Sedating Histamine H1-Recepto Antagonist", Preclinical Efficacy and Antiallergic, J. Allergy Clin. Immunol. (Abstract 1118), Vo.								05		
	No. 1, part 2, pp. S382-383. (2000)								**		
	DB Kubo, et al., "Antimuscarinic Effects of Antihistamines: Quantitative Evaluation by Receptor-Bir Assay", Japan J. Pharmacol., 1987, Vol. 43, pp. 277-282.						tor-Bindi	ng			
	DC	Lathers, et al., "Pharm					ckness". T	iPS. June.	1989. Vo	1. 10.	
2000		pp. 243-250.				_					
0000000	DD	Compounds on the Canine and Rabbit Urinary Bladder", The J. of Urology, August, 1982, Vol. 128. pp. 396-398.									
20000000											
DE Lunde,"Antihistamines", Side Effects of Drugs Annual 14, Elsevier Science Publishers B.V.						V., 1990, pp.					
	DF	135-138. Lunde, "Antihistamine	es" Side Eff	ects of Drugs An	ทมร	1 12: A Worldw	ide Vearly	Survey of	New Da	ta and	
		Trends, Elsevier Scien	ce Publishe	rs B.V., 1998, pp	. 14	12-143.	Ť	•			
0000	DG	67,								logy,	
	DH	August, 1992, Vol. 14 McCue, "Safety of An			of	Allergic Rhiniti	s in Elderl	v Patients'	'. Arch. F	am.	
		Med., September, 199	6, Vol. 5, pp	o. 464-468.							
	DI	Miadonna, et al., "Inhi					n Histamin	e Release	from Hu	man	
	DJ	Basophils", Int. Arch. Mirakhur, et al., "Glyo					naesthesia.	1983. Vo	l. 38, pp.	1195-	
	<u> </u>	1203.						•			
V	DK	Mitchelson, "Pharmac pp. 443-463.				•					
/HS/	DL	Muskat, et al., "The U Vol. 156, pp. 1989-19		lamine in the Tre	atm	ent of Detrusor	Instability'	', The <b>J</b> . o	f Urology	, 1996,	
EXAMINE	R	/Humera Sheikh/		DATE	E C	ONSIDERED	-	m /a = 15 =			
		/Humbia Oneikii/			07/26/2007						
*EXAMIN	ER: I	nitial if reference consid	lered, wheth	er or not citation	is i	n conformance v	with MPEF	609; Dra	w line th	rough	
		conformance and not con									

FORM PTO-1449  U.S. DEPARTMENT OF COMM				ATTY. DOCKE	Г NO.:	SERIAL NO.: TO BE ASSIGNED				
PATENT AND TRADEMARK OF INFORMATION DISCLOSURE STATEMEN				PD01059KQ TO BE ASSIGNED APPLICANT:				<del></del>		
BY APPLICANT			N I	Wing-Kee Ph	nilip Cho					
(Use several sheets if necessary)					FILING DATE: 11/03/2003		GROUP:	:		
U.S. PATENT D				DOCLI			1615			
*EXAMINER		DOCUMENT	DATE	AIENI.				Loun	FILING	OATE IS
INITIAL	Ì	NUMBER	DATE		NAN	/IC	CLASS		APPRO	
		_					l	<u> </u>	L	
	FOREIGN PATENT DOCUMENTS								T==	
		DOCUMENT NUMBER	DATE	COUNTR	₹Y		CLASS	SUB-	TRANSI	ν-
	1	NOWBER		1				CLASS	YES	NO
	OT	HER DOCUMENT	S (Includ	dina Auti	hor Titl	e Date Perti	inent Ps	gas Et	·C )	
/HS/		Nelemans,"Antiallergi	c and antitu	ssive drug						
DI .	<b></b>	Publishers B.V., 1988			150	1 1 111 07			1. 0	
200000	DN	Nomeir, et al., "Influe Extended-Release Tab	nce of Food lets in Healt	on the Ora thy Volunt	al Bioavai teers", J. C	lability of Lorata Clin. Pharm, 1996	dine and P , Vol. 36,	seudoepho No. 10, pr	edrine fro 5. 923-93	· <b>m</b> 0.
00000	DO	Padhi, et al., "Multiple	-Dose Phari	macokinet	ics; Safety	and Tolerance o	f Deslorat	adine in H	[ealthy	
00000		Volunteers (Abstract 1 2, p. S385.	124), Janua	ry, 2000, J	J. Allergy	Clin. Immunol., J	January, 20	000, Vol.	105, No.	1, part
	DP	Parkinson, et al., "Eva						ytochrome	P450 in	Rats
		and Mice", Biochemic								
	DQ	Peggs, et al., "Antihist			the New",	American Family	y Physicia	n,		
	DR	August, 1995, Vol. 52, No. 2, pp. 593-600.  Petrin, "Bewegungskrankheit und ihre Therapie/ Eine Ubersicht (Motion Sickness and its Treatment)",								
	<u> </u>	Schweiz, Rundschau Med., 1974, (PRAXIS) 63, pp. 79-81.								
000000	DS	Quercia, et al., "Focus on Loratadine: A new second-generation nonsedating H1-receptor antagonist", Hosp. Formul., February 1993, Vol. 28, pp. 137, 138, 141, 142, 144, 149, & 153.								
50000000	DT	Remington's Pharmaceutical Sciences. 18th Ed, Alfonso R. Gennaro, Mack Publishing Company, Easton, PA, 1990, pp. 1519-1520.								
000000	DU	Remington's Pharmaceutical Sciences. 18th Ed, Alfonso R. Gennaro, Mack Publishing Company, Easton,								
8	DV	PA, 1990, pp. 1527-1529  Regrick "University incentingnes" The Length Vol. 246, pp. 04-00								
80	DW	Resnick, "Urinary incontinence", The Lancet, July 8, 1995, Vol. 346, pp. 94-99.  Roman, et al., "Loratadine-A Review of Recent Finding in Pharmacology Pharmacokinetics, Efficacy, and							v and	
80000	[ · · ·	Safety, with a Look at its Use in Combination with Pseudoephedrine", Clin. Reviews in Allergy, 1993,								
8000	514	Vol. 11, pp. 89-110.								
000000	DX	Salmun, et al., "Efficacy and Safety of Desloratadine in Seasonal Allergic Rhinitis, January, 2000, J. Allergy Clin. Immunol. (Abstract 1123), Vol. 105, No. 1, Part 2, pp. S384-385.								
000000	DY	Simons, "H1-Receptor Antagonists Comparative Tolerability and Safety", Drug Safety, 1994, Vol. 10, No.								
800.	DZ	5, pp. 350-380 Sunahara, et al., "Phar	macological	l interventi	ions for m	otion sickness. C	ardiovasco	ılar Effect	c" Aviet	ion
XX								ilai Effect	is, Aviat	ion,
0000	EΑ	Space and Environmental Medicine, September, 1987, pp. A270-A276.  Temple, et al., "Loratadine, an Antihistamine, Blocks Antigen-and Ionophore-Induced Leukotriene Release from Human Lung In Vitro", Prostaglandins, 4/1988, 35(4):549-554.								
8	EΒ	Van Cauwenberge, "N					et 1002	Vol 4 No	4 nn 29	23_201
	EC	Van Peer, et al "Keto								
/110/	ED	p. 34. Wade, et al., Handboo								
/HS/	<u> </u>	and Pharma Press, Ro			f G. Brita	in, 1994, pp. 257				
EXAMINE	R /	łumera Sheikh/			DATE C	ONSIDERED	מלמ	מממים		
							U1/2	26/2007		
		nitial if reference consid								rough
		onformance and not con								_

Sheet 6 of 6

FORM PTO-1449  U.S. DEPARTMENT OF COMM PATENT AND TRADEMARK O				ATTY. DOCKE PD01059K Q	SERIAL NO.: TO BE ASSIGNED					
INFORMATION DISCLOSURE STATEME BY APPLICANT				ATEMENT	APPLICANT: Wing-Kee Philip Cho					
(Use several sheets if necessary)				ary)	FILING DATE: 11/03/2003	GROUP: 1615				
			U.S. P	ATENT DOCU	MENTS					
*EXAMINER DOCUMENT NUMBER		DATE NAM		IE CLASS			FILING DATE IF APPROPRIATE			
								ļ		
	L					1				
		F	OREIGN	PATENT DO	CUMENTS					
		DOCUMENT	DATE	COUNTRY		CLASS	SUB-	TRANS	_	
		NUMBER				<u> </u>	CLASS	YES	NO	
	<u> </u>						ļ		-	
		<u>.</u>	-			1	<u> </u>			
	ОТ	HER DOCUMENT	ΓS (Includ	ling Author, Titi	le, Date, Pert	inent Pa	iges, Et	c.)		
/HS/	EE		Wein, "Pharmacology of Incontinence", Urologic Clinics of North America, August, 1995, Vol. 22, No. 3,							
/HS/	EF		Wirth, et al., Mailland Reaction of Lactose and Fluoxeline Hydrochloride, a Secondary Amine, Journal of Pharmaceutical Sciences, Jan. 1998, Vol. 87, No.1, pp.31-39.							
/HS/	EG	Wood, "Antimotion S	Wood, "Antimotion Sickness and Antiemetic Drugs", Drugs, 1979, Vol.17, pp. 471-479.							
/HS/	EH	September 1987, pp. A	Wood, et al., "Mechanisms of Antimotion Sickness Drugs", Aviation, Space, and Environmental Medicine, September 1987, pp. A262-A265.							
/HS/	EI	The United States Pharmacopeia, The United States Formulary, United States Pharmacopeial Convention, Inc., Rockville, MD. 1989, p. 1990.								
/HS/	EJ		Yarker, et al., "Oxybutynin, A Review of its Pharmacodynamic and Pharmacokinetic Properties, and its Therapeutic Use in Detrusor Instability", Drugs and Aging, 1995, Vol. 6, No. 3, pp. 243-262							
/HS/	EK									
EXAMINER /Humera Sheikh/				DATE	CONSIDERED 07/26/2007					
		nitial if reference consideration							rough	